ClinicalTrials.gg
RecruitingNCT07401537Updated Feb 10, 2026

Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer

A Phase 2 interventional study of Extended-Dose Interval Immunotherapy and Standard-Dose Interval Immunotherapy in Triple -Negative Breast Cancer and Breast Cancer, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
416
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 252 studies in Triple Negative Breast Neoplasms with a site in China — 126 open to participants now, 153 under way, 33 of them phase 3. Triple Negative Breast Neoplasms · China.

Planned enrollment
36th of 235
416 · median 90
Started
2025
with 27 others
Phase 2
124 of 252
65 open now
Primary completion
2028-12
later than 132 of 152 live
Registered
226th of 252
by date
Lead sponsor
7 of 252
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Among the 252 studies in Triple Negative Breast Neoplasms with a site in China, this one is the 36th largest by planned enrollment of the 235 interventional ones that give a count, is one of 28 that started in 2025, is one of 124 in phase 2, reaches primary completion later than 132 of the 152 other live ones, and was the 226th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

126 of the 252 studies in Triple Negative Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

121 more — sign in →

All 126 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 252 studies in Triple Negative Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

Triple-negative breast cancer (TNBC), defined by the lack of ER, PR and HER2 expression, is refractory to endocrine therapy and anti-HER2 agents. Chemotherapy was once the mainstay for advanced TNBC, but its limited efficacy necessitates optimized therapeutic strategies. TNBC's high TIL infiltration and elevated PD-L1 expression confer sensitivity to immune checkpoint inhibitors (ICIs), with ICI-chemotherapy combinations initially establishing first-line standard status. Emerging clinical evidence shows that ICI-antibody-drug conjugate (ADC) combinations outperform ICI-chemotherapy regimens, yet immune-related adverse events (irAEs) remain a critical clinical challenge. Expert consensus recommends continuing ICI therapy in advanced TNBC patients achieving CR, PR or SD after ICI-based combination therapy until disease progression or intolerable toxicity. Mechanistically, once ICIs reach target receptor saturation, dose escalation or high-frequency administration fails to boost efficacy but raises toxicity risk. Thus the investigators hypothesize that an ICI maintenance strategy with fixed dose and extended intervals can preserve efficacy, reduce toxicity, improve patient compliance, enhance quality of life and alleviate economic burden for advanced TNBC patients with CR/PR/SD after ICI-chemotherapy or ICI-ADC treatment.

03

Conditions studied

  • Triple -Negative Breast Cancer
  • Breast Cancer

Keywords

  • Immune-checkpoint inhibitors
  • Dose Interval
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary consent to participate in this study and signing of the form.
  2. The age of the signatory of the informed consent form should be ≥18 years old and ≤70 years old.
  3. Advanced (locally recurrent inoperable or ) TNBC confirmed by histology or cytology, defined as ER-negative, PR-negative, and -negative.
  4. IHC detection in tumor tissue with a CPS score ≥1.
  5. Have received standard immunotherapy combined with chemotherapy or immunotherapy combined with ADC and completed 6 cycles, with the last dose administered no more than 28 days before randomization.
  6. The therapeutic efficacy was confirmed as CR, PR or SD after 6-cycle standard treatment according to the v1.1 criteria.
  7. Plan to continue receiving immunotherapy.
  8. An performance-status score of 0 or 1.
  9. The expected survival period exceeds 12 weeks.
  10. Adequate organ function:.
  11. No mental or intellectual abnormalities.
  12. Willing and able to comply with the trial protocol during the trial period.
  13. Female subjects of must agree to use highly effective measures starting at least 7 days before the first dose and continuing until 24 weeks after the last dose. The serum pregnancy test result must be negative within 7 days prior to the first dose.

Exclusion criteria

Exclusion Criteria:

  1. Untreated active or meningeal .
  2. Concomitant other malignant tumors with progression within the recent 5 years or requiring active treatment (excluding adequately treated and controlled carcinoma in situ and non-melanoma skin cancer).
  3. Concomitant severe non-malignant diseases that would affect the patient's compliance or put the patient at risk.
  4. Concomitant active infection.
  5. Receiving other anti-tumor therapies or participating in other interventional clinical trials.
  6. Inflammatory breast cancer.
  7. Dementia, intellectual disability, or any mental disorders that hinder the understanding of the form.
  8. History of allergic reactions to any components of the study drugs or existing to their use.
  9. Presence of any active diseases or history of autoimmune diseases.
  10. Presence of poorly controlled clinical cardiac symptoms or diseases, such as:1) Heart failure of class II or above;2) Unstable angina pectoris;3) Myocardial infarction occurring within 1 year;4) supraventricular or ventricular arrhythmias requiring treatment or intervention.
  11. Presence of grade ≥3 toxicities related to prior treatments that restrict the continuation of maintenance therapy.
  12. History of immunodeficiency, including positivity, active / infection, other acquired or congenital immunodeficiency diseases, and history of organ or stem cell transplantation.
  13. Vaccination with within 4 weeks prior to the administration of study drugs or planned vaccination during the study period.
  14. Prior administration of irinotecan, topotecan, or any other topoisomerase I inhibitors (including topoisomerase I inhibitors), or known history of allergies to the above-mentioned drugs.
  15. Use of systemic at a dose exceeding 10 mg/day of prednisone equivalent within 14 days prior to the administration of study drugs, or planned long-term use of the above dose during the study period (topical, inhaled, or short-term (≤7 days) pulse doses ≤10 mg/day of prednisone equivalent, or physiological dose replacement therapy are allowed for inclusion).
  16. Need for use of any within 14 days prior to the administration of study drugs or planned use during the study period.
  17. Pregnant or lactating women, or women of who refuse to accept measures.
  18. Patients who are difficult or impossible to follow up.
  19. Subjects judged by the investigator to have conditions that may affect compliance or other circumstances making them unsuitable for inclusion.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
416 participants (estimated)

Study arms

  • Experimental
    Extended-Dose Interval

    During the maintenance therapy phase, the dose of PD-1 inhibitors is consistent with that of the standard therapy phase, administered every 6 weeks (q6w); the dose of chemotherapy or TROP2-ADC drugs is consistent with that of the standard therapy phase, administered every 3 weeks (q3w).

    Drug: Extended-Dose Interval Immunotherapy

  • Active comparator
    Standard-Dose Interval

    During the maintenance therapy phase, the dosages of PD-1 inhibitors, chemotherapy, or TROP2-ADC drugs are maintained at the same levels as those in the standard treatment phase, administered every 3 weeks (q3w).

    Drug: Standard-Dose Interval Immunotherapy

Interventions

  • DrugExtended-Dose Interval Immunotherapy

    During the maintenance therapy phase, the dose of PD-1 inhibitors is maintained at the same level as in the standard treatment phase, with the dosing interval extended to every 6 weeks (q6w).

  • DrugStandard-Dose Interval Immunotherapy

    During the maintenance therapy phase, the dosage and dosing interval of PD-1 inhibitors are consistent with those in the standard therapy phase, administered every 3 weeks (q3w).

06

What researchers measure

Primary outcomes

  1. mPFS

    Refers to the time from randomization date to the first observation of disease progression (based on RECIST v1.1 criteria) or death from any cause, whichever occurs first.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.

Secondary outcomes

  1. mOS

    The time from randomization date to any cause of death date.

    Time frame: From date of randomization until the date of death from any cause, assessed up to 3 years.

  2. DoR

    Refers to the time from the date of achieving CR or PR to the first disease progression (PD) or death from any cause, whichever occurs first.

    Time frame: From date of achieving CR or PR until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.

  3. DDC

    Refers to the time from the date of achieving CR, PR, or SD to the first evaluation as PD or death from any cause, whichever occurs first.

    Time frame: From date of achieving CR, PR, or SD until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.

  4. Assessment of quality of life via the EORTC QLQ-C30 questionnaire.

    Patient reported outcomes via the European Organisation for Research and Treatment of Cancer Core Quality of Life questionnaire (EORTC QLQ-C30). It contains 30 items and measures 5 functional scales (physical, role, emotional, cognitive, and social), a global health and quality of life scale, 3 symptom scales (fatigue, nausea/vomiting, and pain), and 6 single items (dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial impact). The global health and quality of life scale uses a 7-point scale scoring with anchors (1=very poor and 7=excellent); the other items are scored on a 4 point scale (1=not at all, 2=a little, 3= quite a bit, 4=very much).

    Time frame: 3 years.

  5. Assessment of quality of life via the EORTC QLQ-BR42 questionnaire.

    Patient reported outcomes via the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Breast Cancer 42 (EORTC QLQ-BR42). It consists of 42 items that formed ten scales (Breast Symptoms, Body Image, Sexual Functioning, Arm Symptoms, Systemic Chemotherapy Side Effects, Hand/Feet Symptoms/Neuropathy, Skeletal Symptoms Scale, Endocrine Symptoms, Breast Satisfaction, Vaginal Symptoms) and 3 single items (Weight Gain, Sexual Enjoyment, and Future Perspective). The items are scored on a 4 point scale (1=not at all, 2=a little, 3= quite a bit, 4=very much).

    Time frame: 3 years.

  6. Assessment of quality of life via the EQ-5D-5L questionnaire.

    Patient reported outcomes via the 5-level EuroQol-5D (EQ-5D-5L questionnaire). It consists of 5 health state dimensions: mobility, self-care, usual activities, pain, and anxiety. Each dimension is rated on a five-point scale from 1 (extreme problem) to 5 (no problem). It also includes a vertical visual analog scale with a graded scoring system: 0 represents the worst imaginable health status, while 100 represents the best.

    Time frame: 3 years.

  7. Assessment of quality of life via the HADS questionnaire.

    Patient reported outcomes via the Hospital anxiety and depression scale (HADS). It is a 14 items questionnaire: 7 items related to anxiety and 7 items related to depression scored on a scale. Each item is rated on a 4-point Likert scale (0 = "not at all", 1 = "a little", 2 = "quite a bit", and 3 = "very much"), with higher scores indicating more distress.

    Time frame: 3 years.

  8. Assessment of quality of life via the FCRI questionnaire.

    Patient reported outcomes via the Fear of Cancer Recurrence Inventory (FCRI). The scale is assessed using a 5-point Likert scale, where level 0 indicates "never or not at all" and level 4 indicates "a lot or always".

    Time frame: 3 years.

  9. AE

    Incidence and severity of adverse events

    Time frame: 3 years.

  10. Cost-Utility Analysis

    Measured by incremental cost-effectiveness ratio (ICER), expressed as the cost per quality-adjusted life year (QALY) gained.

    Time frame: 3 years.

Other outcomes

  1. Biomarker

    Compare the differences in immune cell proportion, PD-1 saturation and other aspects among blood and tissue samples in both arms to identify biomarkers that may predict treatment outcomes.

    Time frame: 3 years (before and after therapy).

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2028, 36 months after the start.

Of 220 non-industry phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's planned 36 months is below that.

Counting every sponsor, half of 255 studies reached it within 59 months; a quarter within 37 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2026
First posted
Feb 10, 2026
StartActual
Dec 31, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07401537
Responsible party
Jieqiong Liu, M.D., Ph.D. (Professor, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University) — Principal investigator
First posted
Feb 10, 2026
Start date
Dec 31, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Feb 10, 2026

Study contacts

Jieqiong Liu
Contact
liujieqiong01@163.com
86-13922272706

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion